Oct. 17, 2007 - Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin.... Merck's Press Release -
Thursday, October 18, 2007
Merck , Supplemental New Drug Applications for JANUVIA
Oct. 17, 2007 - Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA™ (sitagliptin), the only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in combination with insulin.... Merck's Press Release -
